Efficacy and Safety of Secukinumab 150 mg with and Without Loading Regimen in Ankylosing Spondylitis: 104-week Results from MEASURE 4 Study

Table 3 Efficacy endpoints at week 16 by prior TNFi therapy status

Endpoints	TNFi-naive			TNFi-IR
Endpoints	Secukinumab 150 mg (N = 85)	Secukinumab 150 mg no load (N = 85)	Placebo (N = 83)	Secukinumab 150 mg (N = 31)	Secukinumab 150 mg no load (N = 32)	Placebo (N = 34)
ASAS20, %	60.0	62.4	49.4	58.1	59.4	41.2
ASAS40, %	40.0	38.8	30.1	35.5	28.1	23.5
hsCRP (post-baseline/baseline ratio), LS mean ± SE	0.51 ± 1.09*	0.55 ± 1.09*	1.03 ± 1.10	0.76 ± 1.17^‡	0.76 ± 1.17^‡	1.24 ± 1.17
ASAS 5/6, %	37.6	45.9^‡	30.1	35.5	34.4	26.5
BASDAI, LS mean change from baseline ± SE	− 2.54 ± 0.23	− 2.65 ± 0.23	− 2.00 ± 0.23	− 2.08 ± 0.42	− 2.42 ± 0.42	− 1.57 ± 0.40
SF-36 PCS, LS mean change from baseline ± SE	6.74 ± 0.80	7.69 ± 0.81^‡	5.24 ± 0.82	5.21 ± 1.28	6.54 ± 1.26	3.95 ± 1.21
ASQoL, LS mean change from baseline ± SE	− 4.49 ± 0.50	− 5.13 ± 0.50^§	− 3.26 ± 0.51	− 2.72 ± 0.80	− 3.49 ± 0.79	− 2.52 ± 0.76

ASAS Assessment of Spondyloarthritis International Society, ASQoL ankylosing spondylitis quality of life, BASDAI Bath Ankylosing Spondylitis Disease Activity Index, hsCRP high-sensitivity C-reactive protein, IR inadequate responder, LS least squares, N number of patients randomized, SE standard error, SF-36 PCS short form-36 physical component summary, TNFi tumor necrosis factor-alpha inhibitors
^*P < 0.0001; ^§P < 0.01; ^‡P < 0.05 versus placebo (P values are unadjusted). Non-responder imputation (binary variables) and mixed-effect model repeated measures (continuous variables) analyses presented